Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 8/20 | 0.64 |
| ▸ | DPP4 | P27487 | 1/20 | 0.58 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.58 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.50 |
| ▸ | LAP3 | P28838 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GRM8 | O00222 | 1/20 | 0.48 |
| ▸ | GRM6 | O15303 | 1/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.48 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30676233 | 1.00 | FOLH1 (0.64) | FOLH1DPP4DPP8DPP9ALDH1A1 | |
| SCHEMBL537147 | 1.00 | FOLH1 (0.64) | FOLH1DPP4DPP8DPP9ALDH1A1 | |
| SCHEMBL29796607 | 0.97 | FOLH1 (0.60) | FOLH1DPP4DPP8DPP9ALDH1A1 | |
| SCHEMBL31195712 | 0.97 | FOLH1 (0.60) | FOLH1DPP4DPP8DPP9ALDH1A1 | |
| SCHEMBL30784907 | 0.97 | FOLH1 (0.60) | FOLH1DPP4DPP8DPP9ALDH1A1 | |
| Leucine SCHEMBL14126311 | 0.95 | FOLH1 (0.59) | FOLH1DPP4DPP8DPP9ALDH1A1 | |
| SCHEMBL29400510 | 0.95 | FOLH1 (0.63) | FOLH1DPP4DPP8DPP9NAALAD2 | |
| Leucine SCHEMBL14126312 | 0.95 | FOLH1 (0.59) | FOLH1DPP4DPP8DPP9ALDH1A1 | |
| SCHEMBL5329396 | 0.94 | FOLH1 (0.57) | FOLH1DPP4DPP8DPP9BACE1 | |
| SCHEMBL29441706 | 0.94 | FOLH1 (0.57) | FOLH1DPP4DPP8DPP9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118897023-B | Method for directly measuring alpha and gamma-glutamyl peptide in skeletal muscle by using LC-MS and isotope dilution assay | 中国农业科学院北京畜牧兽医研究所 | 2025-03-25 | — | — | CN | claimed |
| US-20250027938-A1 | METABOLIC SIGNATURE FOR PREDICTION OF MUCOSAL INFLAMMATION AND MICROBIAL COMPOSITION | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2025-01-23 | — | — | US | claimed |
| CN-118897023-A | Method for directly measuring alpha and gamma-glutamyl peptide in skeletal muscle by using LC-MS and isotope dilution assay | 中国农业科学院北京畜牧兽医研究所 | 2024-11-05 | — | — | CN | claimed |
| EP-4370919-A1 | METABOLIC SIGNATURE FOR PREDICTION OF MUCOSAL INFLAMMATION AND MICROBIAL COMPOSITION | Imperial College Innovations Limited (GB) | 2024-05-22 | — | — | EP | claimed |
| WO-2023285832-A1 | METABOLIC SIGNATURE FOR PREDICTION OF MUCOSAL INFLAMMATION AND MICROBIAL COMPOSITION | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-01-19 | — | — | WO | claimed |
| EP-3987064-A1 | METHOD FOR DIAGNOSING ESTHETIC DEGRADATIONS OF SKIN | L'OREAL (FR) | 2022-04-27 | — | — | EP | claimed |
| WO-2020260355-A1 | METHOD FOR DIAGNOSING ESTHETIC DEGRADATIONS OF SKIN | L'OREAL (FR) | 2020-12-30 | — | — | WO | claimed |
| US-20190120855-A1 | Biomarkers for Fatty Liver Disease and Methods Using the Same | THE CLEVELAND CLINIC FOUNDATION | 2019-04-25 | — | — | US | claimed |
| US-9977034-B2 | Biomarkers for fatty liver disease and methods using the same | Meabolon, Inc. (US) | 2018-05-22 | — | — | US | claimed |
| US-20150377910-A1 | Biomarkers for Fatty Liver Disease and Methods Using the Same | METABOLON, INC. | 2015-12-31 | — | — | US | claimed |
| EP-2546649-B1 | Biomarkers for fatty liver disease and methods using the same | METABOLON INC (US) | 2015-02-25 | — | — | EP | claimed |
| WO-2013188333-A1 | BIOMARKERS RELATED TO NEPHROTOXICITY AND METHODS USING THE SAME | METABOLON, INC. (US) | 2013-12-19 | — | — | WO | claimed |
| WO-2013155528-A2 | METHODS FOR REDUCING BRAIN INFLAMMATION, INCREASING INSULIN SENSITIVITY, AND REDUCING CERAMIDE LEVELS | FASGEN, INC. (US) | 2013-10-17 | — | — | WO | claimed |
| EP-2546649-A2 | Biomarkers for fatty liver disease and methods using the same | Metabolon Inc. (US) | 2013-01-16 | — | — | EP | claimed |
| EP-2227689-B1 | BIOMARKERS FOR FATTY LIVER DISEASE AND METHODS USING THE SAME | METABOLON INC (US) | 2012-12-26 | — | — | EP | claimed |
| US-20100279956-A1 | Biomarkers For Fatty Liver Disease And Methods Using The Same | METABOLON, INC. | 2010-11-04 | — | — | US | claimed |
| CN-122045749-A | Method for identifying key flavor substances of rice based on materially group science and machine learning | 华中农业大学 | 2026-05-15 | — | — | CN | disclosed |
| US-12534439-B2 | Xanthohumol derivatives and methods for making and using | OREGON STATE UNIVERSITY (US) | 2026-01-27 | — | — | US | disclosed |
| WO-1997031938-A9 | OLIGOPEPTIDES FOR DRUG DELIVERY | — | 1997-11-20 | — | — | WO | disclosed |
| WO-1997031938-A1 | OLIGOPEPTIDES FOR DRUG DELIVERY | EMISPHERE TECHNOLOGIES, INC. (US) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534439-B2 | Xanthohumol derivatives and methods for making and using | MT-CO1, MT-CO2, PC | FOLH1 3243/4885DPP4 1656/4885DPP8 1136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.